The median PFS was 211 (95% CI, 177 to 281) days among patients with low tumor CcO activity and 222 (95% CI, 168 to 297) days among patients with high tumor CcO activity (P = .85 by log-rank test) (Figure 1D). The gene discussed is RYR1; the disease is neoplasm.